Altimmune Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Altimmune Inc's ROI in the second quarter of 2026?
Altimmune Inc recorded a cumulative net loss of $-92 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -27.4%.

Within the Healthcare sector 357 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3421 to 3587.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	118.28 %	74.17 %	38.67 %	2.26 %	-10.85 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	515	334	277	214	189
Return On Investment (TTM)	-27.4 %	-35.91 %	-42.12 %	-48.78 %	-57.19 %
ALT's Overall Ranking	# 3587	# 3421	# 3271	# 3483	# 3062
Seq. Investment Change TTM	32.06 %	21.27 %	21.56 %	12.12 %	5.38 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-92	-91	-88	-84	-88

ALT Company Profile >> Back to ALT Roi Comparisons >> See Annual ALT Return On Investment

Return On Investment ALT's Ranking
Within:	No.
Industry	# 138
Sector	# 358
Overall	# 3587

Return On Investment Statistics
High	Average	Low
3.57 %	-45.41 %	-97.94 %
(Mar 31 2013)		(Jun 30 2018)

News about Altimmune inc Return on Investment ROI

Unexpected Loss: Altimmune's Chief Financial Officer Richard Eisenstadt Passes Away While Company Faces Financial Challenges.

June 26, 2024

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Facts:
- Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt.
- Richard Eisenstadt s untimely death occurred on Monday, June 24, 2024.
- Altimmune Inc recorded a cumulative net loss of $93 million during the 12 months ending in the first quarter of 2024.
- This negative financial performance resulted in a negative return on investment (ROI) of -52.85%

Honoring the Legacy of Dr. Stephen Harrison: Pioneering Scientist and Catalyst for Medical Advancements

April 25, 2024

In a shocking turn of events, the medical community is mourning the untimely demise of Dr. Stephen Harrison, a brilliant mind and a remarkable innovator in the field of medicine. Altimmune, a biopharmaceutical company at the forefront of cutting-edge research, acknowledges the immense loss and pays tribute to this remarkable scientist, whose contributions have left an indelible mark on the healthcare industry. Dr. Harrison s unexpected passing has sent shockwaves across the scientific community, prompting reflection on his exceptional achievements and laying a foundation for a prospective future in medical advancements.
A Life Dedicated to Transformative Medical Breakthroughs:
Born with an insatiable curiosity and tenacious scientific spirit, Dr. Stephen Harrison embarked on a journey that would revolutionize healthcare. Graduating with top honors from renowned universities, Dr. Harrison s academic prowess served as a prelude to his illustrious career. He pursued a relentless pursuit of knowledge, specializing in areas such as virology, immunology, and biochemistry, which eventually earned him a distinguished reputation as a visionary in the field.

Financial Statements
Altimmune Inc's II. Quarter Investments	$ 515 Millions	ALT's Balance sheet
Altimmune Inc's II. Quarter Income	$ -23 Millions	Quarterly ALT's Income Statement
ALT's Income by Division		See ALT's Income by Division

ALT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	265	129	198	190	201
Y / Y Investment Growth	105.63 %	-35.09 %	4.54 %	-5.34 %	-13.95 %
Net Income in Millions	-88	-95	-88	-85	-97
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-33.25 %	-73.78 %	-44.56 %	-44.62 %	-48.4 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ALT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ALT's Competitors
Subscribers only: Roi for Altimmune Inc's Suppliers
Subscribers only: Return On Investment for ALT's Customers

Other Ratios
ALT's Roa	ALT's Inventory Turnover Ratio	ALT's Growth Rates	ALT's Dividend Statistics
	ALT's Profitability Ratios	ALT's Asset Turnover Ratio	ALT's Dividend Growth
ALT's Roe	ALT's Valuation Ratios	ALT's Financial Strength Ratios	ALT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-12T06:15:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.